3 recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 3 |
Follow Immunocore Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adjuvant Tebentafusp in High Risk Ocular Melanoma Tebentafusp - Uveal Melanoma | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 290 | 2024-11-11 | 2026-06-30 |
| IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) Brenetafusp, Nivolumab, Nivolumab + Relatlimab - Advanced Melanoma | Phase 3 | Recruiting | Immunocore Ltd | 680 | 2024-06-05 | 2026-02-25 |
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice - Advanced Melanoma | Phase 3 | Recruiting | Immunocore Ltd | 540 | 2022-12-19 | 2026-02-25 |
Melanoma (1) · Nevus, Blue (1) · Uveal Melanoma (1)
tebentafusp (2) · Nivolumab (1) · Opdualag (1) · pembrolizumab (1) · relatlimab (1)
Belgium (3) · France (3) · Germany (3) · Poland (3) · Spain (3) · United Kingdom (3) · United States (3) · Australia (2) · Austria (2) · Canada (2) · Italy (2) · Sweden (2) · Switzerland (2) · Argentina (1) · Brazil (1)
Paul Nathan (1) · Richard D. Carvajal (1) · Serge Leyvraz (1)
2023 (1)